Claims for Patent: 5,576,193

Summary for Patent: 5,576,193

Title:	Protein having human plasmin inhibiting activity
Abstract:	A protein having human plasmin inhibiting activity, substantially equivalent reactivity with human plasmin to a human .alpha..sub.2 -plasmin inhibitor derived from plasma, a binding ability to human fibrin about 1/4 to about 1/3 of that of the human .alpha..sub.2 -plasmin inhibitor derived from plasma, and a molecular weight of about 50,000 to about 77,000.
Inventor(s):	Sumi; Yoshihiko (Hino, JP), Ichikawa; Yataro (Tokorozawa, JP), Aoki; Nobuo (Tokyo, JP), Muramatsu; Masami (Tokorozawa, JP)
Assignee:	Teijin Limited (JP)
Application Number:	08/437,234
Patent Claims:	1. A DNA fragment encoding an isolated, substantially pure recombinant protein having human plasmin inhibiting activity of about 70 to 110% of the reactivity with human plasmin to human .alpha..sub.2 -plasmin inhibitor derived from plasma, capable of binding to human fibrin at a level of about 1/4 to about 1/3 of that of the human .alpha..sub.2 -plasmin inhibitor derived from plasma, when measured by the amount of I.sup.125 labelled protein taken up into a fibrin clot, by means of a gamma-counter, and a molecular weight of about 50,000 to about 77,000. 2. The DNA fragment of claim 1 containing a DNA sequence of the following formula encoding the following amino acid sequence, optionally via an intron: ##STR4## 3. A DNA of claim 2 composed of a DNA fragment derived from a chromosome and shown in FIGS. 4A-4D of the accompanying drawing and an EcoRI-(EcoRI linker) portion of human .alpha..sub.2 -plasmin inhibitor cDNA shown in FIG. 5 of the accompanying drawing. 4. pSV2PI vector. 5. A process for producing an isolated, substantially pure recombinant protein having human plasmin inhibiting activity of about 70 to 110% of the reactivity with human plasmin to human .alpha..sub.2 -plasmin inhibitor derived from plasma, capable of binding to human fibrin at a level of about 1/4 to about 1/3 of that of the human .alpha..sub.2 -plasmin inhibitor derived from plasma, when measured by the amount of I.sup.125 labelled protein taken up into a fibrin clot, by means of a gamma-counter, and a molecular weight of about 50,000 to about 77,000 which comprises cultivating animal cells transfected by an expression vector harboring the DNA fragment of claim 1. 6. The process of claim 5 in which the expression vector is pSV2PI. 7. The process of claim 5 in which the cells are BHK, CHO, 293, Cang Liver or HeLa cells.

Details for Patent 5,576,193

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2013-11-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2013-11-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2013-11-19